A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients

This paper introduces a two-part mixture model using a Markov model to describe cytokine release syndrome (CRS) incidence and progression following elranatamab treatment, a bispecific antibody (BsAb). The model found that increased elranatamab exposure correlated with a higher probability of CRS, while premedication reduced this risk. This approach can characterize longitudinal CRS events and may help optimize dose-priming regimens for future BsAbs in clinical development.